Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI scans may reveal hidden clues to myeloma relapse risk

NCT ID NCT07746232

Knowledge-focused Sponsor: Fondazione EMN Italy Onlus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely to come back. By following patients over time, researchers hope to see if these imaging markers can identify those who need closer monitoring or different treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion-weighted whole-body MRI (DW-MRI) and fat fraction measurement
What this could lead to
If successful, this could establish MRI as a reliable tool to predict which myeloma patients are at higher risk of relapse after transplant, enabling more personalized follow-up and treatment.
What could go wrong
This is an observational study, so it won't test a new treatment. The predictive value of the MRI measures is not yet proven, and results may not change current practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for transplantation and have been treated according to the most recent standards of care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Newly diagnosed MM participants eligible for ASCT, treated with anti-CD38-based quadruplet induction therapy and ASCT, with post-ASCT/premaintenance DW-MRI available (in tandem ASCT, DW-MRI after second ASCT will be considered). * Age ≥18 years. * Participant must sign an informed consent form (ICF) that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial. Exclusion Criteria: \- Absence of post-ASCT/pre-maintenance DW-MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma (MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma (MM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • A.O. Spedali Civili di Brescia

    Brescia, Italy

  • A.O.U. Maggiore della Carità

    Novara, Italy

  • A.O.U. di Bologna - Policlinico S. Orsola Malpighi

    Bologna, Italy

  • ASL Roma 1

    Rome, Italy

  • I.R.C.C.S. Ospedale S. Raffaele

    Milan, Italy

  • IRCCS Istituto Tumori "G. Paolo II - U.O.C. Ematologia e Terapia Cellulare

    Bari, Italy

  • Istituto Oncologico Veneto IRCCS - UOC Oncoematologia

    Castelfranco Veneto, Italy

  • Ospedale Classificato Valduce

    Como, Italy

  • Ospedale Niguarda

    Milan, Italy

  • Policlinico S. Matteo Fondazione IRCCS

    Pavia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.